Most Read Articles
Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
27 Sep 2019
Quadrivalent influenza vaccine (split virion, inactivated) 0.5 mL inj
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.
Stephen Padilla, 17 Dec 2019
The use of aspirin for primary prevention in patients without known cardiovascular diseases (CVDs) significantly reduces the risk of myocardial infarction (MI) but increases that of major bleeding and haemorrhagic stroke, according to a meta-analysis.

Isradipine fails to slow Parkinson’s disease progression

Roshini Claire Anthony
15 May 2019

Use of the antihypertensive drug isradipine did not reduce the progression of Parkinson’s disease, according to the STEADY-PD III* study presented at the American Academy of Neurology annual meeting (AAN 2019).

“Unfortunately, the people who were taking isradipine did not have any difference in their Parkinson’s symptoms over the 3 years of the study compared to the people who took a placebo,” said study author Professor Tanya Simuni, chief of movement disorders at the Department of Neurology, Northwestern University Feinberg School of Medicine in Chicago, Illinois, US.

Participants in this phase III study conducted at 54 sites in the US and Canada were 336 patients (mean age 62 years, 68 percent male, mean Unified Parkinson Disease Rating Scale [UPDRS] part I–III score, 23.1) newly diagnosed with Parkinson’s disease (mean 0.9 years since Parkinson’s disease diagnosis) who were randomized 1:1 to receive the dihydropyridine calcium channel antagonist isradipine at a dose of 10 mg/day or placebo for 36 months.

At 36 months, there was no difference in the UPDRS part I–III score between patients who received isradipine and placebo (mean change from baseline, 2.99 vs 3.26 points, treatment effect, 0.27 points, 95 percent confidence interval, -2.5 to 3.0; p=0.85). [AAN 2019, Clinical Trials Plenary Session]

Other secondary endpoints such as time to and need for dopaminergic therapy, time to initial motor complications, changes in non-motor disability, and quality of life were also similar between patients who received isradipine and placebo. The most notable adverse effect among patients who received isradipine was oedema.

The study was undertaken based on previous research that has suggested that calcium channel blockers were associated with a reduced risk of Parkinson’s disease. [Neurology 2008;70(16 Pt 2):1438-1444; Ann Neurol 2010;67:600-606; Am J Epidemiol 2012;175:627-635] Isradipine, specifically, has shown signs of reducing the risk of Parkinson’s disease in animal models. [Neurobiol Dis 2011;43:364-371]

“Of course, this [result] is disappointing news for everyone with Parkinson’s disease and their families, as well as the research community,” said Simuni. “However, negative results are important because they provide a clear answer, especially for [a] drug that is commercially available. We will all continue to work to find a treatment that can slow down or even cure this disease,” she said.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
27 Sep 2019
Quadrivalent influenza vaccine (split virion, inactivated) 0.5 mL inj
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.
Stephen Padilla, 17 Dec 2019
The use of aspirin for primary prevention in patients without known cardiovascular diseases (CVDs) significantly reduces the risk of myocardial infarction (MI) but increases that of major bleeding and haemorrhagic stroke, according to a meta-analysis.